abagovomab

Home
Ligands
abagovomab

GtoPdb Ligand ID: 8265

Synonyms: ACA125 | MEN-2234

Comment: Abagovomab is an anti-idiotype monoclonal antibody. The antibody is designed to functionally mimic the epithelial ovarian cancer antigen CA-125 (aka mucin 16: MUC16, Q8WXI7) [1,3,5].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

References
1. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]
2. Buzzonetti A, Fossati M, Catzola V, Scambia G, Fattorossi A, Battaglia A. (2014) Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial. Cancer Immunol Immunother, 63 (10): 1037-45. [PMID:24952307]
3. Flemming J, Groger K, Schmitz R, Manzini S. (2009) Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminium. Patent number: US20090104184. Assignee: Menarini International Operations Luxembourg S.A.. Priority date: 29/06/2006. Publication date: 23/04/2009.
4. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D et al.. (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol, 31 (12): 1554-61. [PMID:23478059]
5. Schlebusch H, Reinartz S, Kaiser R, Grünn U, Wagner U. (1997) Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique. Hybridoma, 16 (1): 47-52. [PMID:9085128]
6. Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Möbus V, Kreienberg R et al.. (2001) Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clin Cancer Res, 7 (5): 1154-62. [PMID:11350879]
7. Wagner U, Schlebusch H, Köhler S, Schmolling J, Grünn U, Krebs D. (1997) Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma, 16 (1): 33-40. [PMID:9085126]

References

1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]

2. Buzzonetti A, Fossati M, Catzola V, Scambia G, Fattorossi A, Battaglia A. (2014)
Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Cancer Immunol Immunother, 63 (10): 1037-45. [PMID:24952307]

3. Flemming J, Groger K, Schmitz R, Manzini S. (2009)
Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminium.
Patent number: US20090104184. Assignee: Menarini International Operations Luxembourg S.A.. Priority date: 29/06/2006. Publication date: 23/04/2009.

4. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D et al.. (2013)
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.
J Clin Oncol, 31 (12): 1554-61. [PMID:23478059]

5. Schlebusch H, Reinartz S, Kaiser R, Grünn U, Wagner U. (1997)
Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique.
Hybridoma, 16 (1): 47-52. [PMID:9085128]

6. Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Möbus V, Kreienberg R et al.. (2001)
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Clin Cancer Res, 7 (5): 1154-62. [PMID:11350879]

7. Wagner U, Schlebusch H, Köhler S, Schmolling J, Grünn U, Krebs D. (1997)
Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Hybridoma, 16 (1): 33-40. [PMID:9085126]